Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis

Further Publications Dermatology

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Lancet

Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB

doi: 10.1016/S0140-6736(21)00578-X

Systemic Lupus Erythematosus

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Ann Rheum Dis.

Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)

doi: 10.1136/annrheumdis-2020-217101.

Systemic Lupus Erythematosus

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Arthritis Rheumatol.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D

doi: 10.1002/art.40049.

Rheumatoid Arthritis

Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT)

Ann Rheum Dis.

Hewlett S, Almeida C, Ambler N, Blair PS, Choy EH, Dures E, Hammond A, Hollingworth W, Kadir B, Kirwan JR, Plummer Z, Rooke C, Thorn J, Turner N, Pollock J, RAFT Study Group

doi: 10.1136/annrheumdis-

Allergic DiseasesImmunotherapy

Intralymphatic Immunotherapy improves grass pollen allergic rhinoconjunctivitis. A three-year randomized placebo-controlled trial

J Allergy Clin Immunol.

Skaarup SH, Schmid JM, Skjold T, Graumann O, Hoffmann HJ

doi: 10.1016/j.jaci.2020.07.002.

COMMENTED

Immunosuppressive treatment for proliferative lupus nephritis

Cochrane Database Syst Rev.

Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF

doi: 10.1002/14651858.

Systemic Lupus Erythematosus

Sub-Setting Systemic Lupus Erythematosus by Combined Molecular Phenotypes Defines Divergent Populations in Two Phase III Randomized Trials

Rheumatology (Oxford)

Petri M, Watts SD, Higgs RE, Linnik MD

doi: 10.1093/rheumatology/keab144

Long-term clinical outcomes of imiquimod 5% cream versus diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials

J Eur Acad Dermatol Venereol.

Gollnick H, Dirschka T, Ostendorf R, Kerl H, Kunstfeld R

doi: 10.1111/jdv.15868.

Psoriasis

Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial

Br J Dermatol.

Gottlieb AB, Kubanov A, van Doorn M, Sullivan J, Papp KA, You R, Regnault P, Frueh JA

doi: 10.1111/bjd.18331.

Related content

Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: A randomized, double-blind, placebo-controlled, 52-week study.

Reducing arthritis fatigue impact: two-year randomised controlled trial of cognitive behavioural approaches by rheumatology teams (RAFT)

Intralymphatic Immunotherapy improves grass pollen allergic rhinoconjunctivitis. A three-year randomized placebo-controlled trial

Immunosuppressive treatment for proliferative lupus nephritis

Sub-Setting Systemic Lupus Erythematosus by Combined Molecular Phenotypes Defines Divergent Populations in Two Phase III Randomized Trials

Long-term clinical outcomes of imiquimod 5% cream versus diclofenac 3% gel for actinic keratosis on the face or scalp: a pooled analysis of two randomized controlled trials

Sustained Efficacy of Secukinumab in Subjects with Moderate-to-Severe Palmoplantar Psoriasis: 2·5-Year Results from GESTURE, a Randomized, Double-blind, Placebo-controlled Trial